Vertex Pharmaceuticals (VRTX)

AI-powered earnings call analysis for Vertex Pharmaceuticals. Get insights from quarterly earnings reports with our AI-generated podcast. Educational content only - not investment advice.

10 episodes 5 languages

Next Episode

Vertex Pharmaceuticals earnings call scheduled for Aug 3, 2026 (after market close)

New episode expected Aug 4, 2026

Latest Episode

Q1 2026 Earnings

7:46 • 5/5/2026

Vertex Pharmaceuticals (VRTX) - Q1 2026

0:00

7:46

Speed:

Q1 2026 Earnings

10:30 • 2026/5/5

Vertex Pharmaceuticals (VRTX) - Q1 2026

0:00

10:30

Speed:

Q1 2026 Earnings

11:58 • 05/05/2026

Vertex Pharmaceuticals (VRTX) - Q1 2026

0:00

11:58

Speed:

Q1 2026 Earnings

11:25 • 5/5/2026

Vertex Pharmaceuticals (VRTX) - Q1 2026

0:00

11:25

Speed:

Q1 2026 Earnings

8:50 • 5.5.2026

Vertex Pharmaceuticals (VRTX) - Q1 2026

0:00

8:50

Speed:

All Episodes

EN - English (2) CN - 中文 (2) FR - Français (2) ES - Español (2) DE - Deutsch (2)

Q1 2026 Earnings

7:46

Vertex achieved strong Q1 2026 results with $2.99B revenue (+8% YoY) and $4.47 adjusted EPS, driven by CF leadership and rapid commercial uptake of new therapies KASJEVY and GERNAVICS, while povitacicept demonstrated compelling Phase III IgAN efficacy with fastest BLA filing in company history.